NCT04709536View on ClinicalTrials.gov

A Study of IBI306 in Participants With Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

November 9, 2021

Study Completion Date

January 28, 2022

Conditions
Hypercholesterolemia
Interventions
DRUG

IBI306

Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24

DRUG

Placebo

Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04709536 - A Study of IBI306 in Participants With Hypercholesterolemia | Biotech Hunter | Biotech Hunter